MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH

NCT04085601 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2022-10-21

Study results available
· View outcomes & findings →

Summary

Evaluation of the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria .

Conditions

Interventions

DRUG

APL-2

Complement (C3) Inhibitor

Sponsors & Collaborators

  • Apellis Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-27
Primary Completion
2021-06-23
Completion
2021-06-23
FDA Drug
Yes

Countries

  • Colombia
  • Hong Kong
  • Malaysia
  • Mexico
  • Peru
  • Philippines
  • Poland
  • Serbia
  • Singapore
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04085601 on ClinicalTrials.gov